Search results for "Guidelines as Topic"

showing 10 items of 372 documents

Overcoming barriers to evidence-based patient blood management: a restricted review

2020

Abstract Background Blood transfusions are associated with a range of adverse patient outcomes, including coagulopathy, immunomodulation and haemolysis, which increase the risk of morbidity and mortality. Consideration of these risks and potential benefits are necessary when deciding to transfuse. Patient blood management (PBM) guidelines exist to assist in clinical decision-making, but they are underutilised. Exploration of barriers to the implementation and utilisation of the PBM guidelines is required. This study aimed to identify common barriers and implementation strategies used to implement PBM guidelines, with a comparison against current expert opinion. Methods A restricted review a…

Health Knowledge Attitudes PracticeEvidence-based practiceMEDLINEHealth Informatics030204 cardiovascular system & hematologyCochrane LibraryHealth informaticsImplementation StrategiesConsolidated Framework for Implementation ResearchHealth administration03 medical and health sciences0302 clinical medicineNursingExpert Recommendations for Implementing ChangePatient blood managementMedicineHumansBlood Transfusion030212 general & internal medicineImplementation Sciencelcsh:R5-920business.industryHealth PolicyPublic Health Environmental and Occupational HealthHealth services researchGeneral MedicineHaemolysisOrganizational CultureVDP::Medisinske Fag: 700::Helsefag: 800Practice Guidelines as TopicBarrier MappingImplementation researchSystematic ReviewGuideline Adherencebusinesslcsh:Medicine (General)
researchProduct

Cardiovascular risk in patients without known cardiovascular disease.

2014

Understanding the risks of atherosclerotic cardiovascular disease (CVD) allows for better patient education and management. Multiple risk models have been validated in large patient populations and provide insights into the risks associated with CVD. When assessing such risks, we suggest using a model that predicts myocardial infarction, cardiovascular death, and/or cerebrovascular events. In this review, we analyze several risk models and stratify the risks associated with CVD. We suggest that appropriate profiling of patients at-risk of CVD will lead to better physician recognition and treatment of modifiable risk factors, appropriate application of ATP III treatment for hyperlipidemia, a…

Health Knowledge Attitudes PracticeRisk FactorModels TheoreticalCoronary heart diseaseMyocardial infarctionPatient Education as TopicCardiovascular DiseasesRisk FactorsCardiovascular DiseasePractice Guidelines as TopicBorderline risk factorHumansC Reactive ProteinCardiovascular multiple risk factorHumanEuropean review for medical and pharmacological sciences
researchProduct

Urticaria in children and adolescents: An updated review of the pathogenesis and management

2018

The present survey represents the latest data on diagnosis and management of childhood urticaria. It has been observed that urticaria occurs less often in children than adults, with symptoms rarely lasting for over 6 weeks. Triggers or aggravating factors can be found only in 21%-55% of cases. Finding autoantibodies in children does not impact a disease prognosis, unlike in adult patients, where the presence of autoantibodies is associated with a more prolonged run of the disease, a more severe prognosis and more intensive treatment methods. The incidence of food allergy equals to 8%-10% of cases. The incidence of Helicobacter Pylori infection in children is lower than that in adults and co…

Helicobacter pylori infectionPediatricsmedicine.medical_specialtyAdolescentUrticariaImmunologyOmalizumabDiseaseDiagnosis DifferentialPathogenesis03 medical and health sciences0302 clinical medicineFood allergyAnti-Allergic AgentsmedicineHumansImmunology and Allergy030212 general & internal medicineAggravating FactorChildbusiness.industryIncidence (epidemiology)Prognosismedicine.disease030228 respiratory systemChronic DiseasePractice Guidelines as TopicPediatrics Perinatology and Child HealthEtiologybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct

Bone marrow biopsy in Hodgkin's lymphoma.

2004

In the study of patients with Hodgkin's lymphoma (HL) the evaluation of bone marrow biopsy (BMB) can be difficult. In this review we analyze the main diagnostic features and the clinical risk factors of BM involvement. Although the role of BMB is criticized by some authors, its value is irreplaceable in the staging of HL and in the diagnosis of primary medullary HL. The Ann Arbor staging committee criteria should be revised and updated in the light of the current immunohistochemical studies that give a fundamental help in the diagnostic process. A single BMB should be adequate for diagnosis in most instances. In cases of suspicious involvement a controlateral BMB could be performed.

Hodgkin's lymphoma.Diagnosis DifferentialPractice Guidelines as TopicHumansBone marrowbiopsyBone Marrow ExaminationHodgkin DiseaseImmunophenotypingEuropean journal of haematology
researchProduct

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper fr…

2014

Item does not contain fulltext AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. METHODS AND RESULTS: Early diagn…

Homozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MipomersenLipoprotein apheresisGene FrequencyDiagnosisconsensuMedicineChildPhenotypic heterogeneityCiències de la salutAnticholesteremic AgentsHomozygoteCiencias de la saludPedigree3. Good healthEuropePhenotypeCardiovascular DiseasesPractice Guidelines as TopicBlood Component Removallipids (amino acids peptides and proteins)HipercolesterolèmiaHIPERCOLESTEROLEMIA (DIAGNÓSTICO)Cardiology and Cardiovascular MedicineLipoprotein apheresismedicine.medical_specialtyConsensusClinical UpdateEvinacumabReviewsguide line1102 Cardiovascular Medicine And Haematology1016-5169Diagnosis DifferentialHyperlipoproteinemia Type IIGenetic HeterogeneityArcus SenilisHomozygous familial hypercholesterolaemiaGeneticsXanthomatosisHumansGynecologybusiness.industryStatinsHealth sciencesCholesterol LDLAtherosclerosisEzetimibeLomitapideLiver TransplantationEarly DiagnosisCardiovascular System & HematologyHomozygous familial hypercholesterolaemia; consensus; guide lineMutationEuropean atherosclerosis societybusinessAterosclerosiEuropean Heart Journal
researchProduct

Dyslipidemia management with medical nutrition therapy: current status and perspectives

2013

In Italy, patients with dyslipidennia account for 15-20% of the adult population with major healthcare and socio-economic impact. According to the ESC/EAS guidelines for the management of dyslipidemias, desirable cholesterol and triglyceride levels can be achieved with a synergy between drug treatment and adequate diet therapy. However, what diets should be adopted? In this review article, different types of dietary treatments are compared, with a special focus on diet education. The new scientific frontier of nutrigenetics is also discussed.

IncidenceCholesterol HDLCholesterol LDLDiet dyslipidemia metabolic syndrome nutrition obesityDiet MediterraneanDietDiet Carbohydrate-RestrictedNutrigenomicsItalyPatient Education as TopicPractice Guidelines as TopicHumansNutrition TherapyDiet Fat-RestrictedLife StyleBiomarkersTriglyceridesDyslipidemias
researchProduct

Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer

2021

Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at a…

InfertilityAdultMalemedicine.medical_specialtyAdolescentfertility preservationmedia_common.quotation_subjectMEDLINEMedizinFertilityGuidelines as Topic03 medical and health sciences0302 clinical medicineCancer SurvivorsSDG 3 - Good Health and Well-beingNeoplasmsMedicineHumansgonadotoxic therapiesFertility preservationYoung adultGrading (education)Childmedia_commonchildhoodCancer030219 obstetrics & reproductive medicinebusiness.industryCancerGuidelinemedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicineDisease Progressionyoung adultFemalebusinessinfertilityreproductive medicineThe Lancet Oncology
researchProduct

[Fertility preservation in the oncology patient].

2017

In recent years, medical advances have substantially improved survival of cancer patients, generating growing concern about the quality of life of the survivors. Increased attention has been paid to reproductive problems after oncological treatments. International guidelines on fertility preservation in cancer patients require that healthcare teams discuss, as early as possible, the impact of cancer treatments on fertility and encourage access to fertility preservation techniques. The development of these techniques in women is a recent effort and many patients and health care providers are not familiar with their rapid expansion. This article discusses indications, results, and risks of th…

Infertilitymedicine.medical_specialtyInternationalitymedia_common.quotation_subjectlcsh:MedicineImproved survivalFertility03 medical and health sciences0302 clinical medicineCancer SurvivorsNeoplasmsHealth caremedicineHumansFertility preservationIntensive care medicinemedia_commonlcsh:R5-920030219 obstetrics & reproductive medicinebusiness.industryRapid expansionlcsh:RCancerFertility PreservationGeneral Medicinemedicine.diseasefemaleFertility030220 oncology & carcinogenesisPractice Guidelines as TopicQuality of Lifeinfertilitylcsh:Medicine (General)businessMedwave
researchProduct

Classification or non-classification of substances with positive tumor findings in animal studies: Guidance by the German MAK commission

2019

One of the important tasks of the German Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (known as the MAK Commission) is in the evaluation of a potential for carcinogenicity of hazardous substances at the workplace. Often, this evaluation is critically based on data on carcinogenic responses seen in animal studies and, if positive tumor responses have been observed, this will mostly lead to a classification of the substance under investigation into one of the classes for carcinogens. However, there are cases where it can be demonstrated with a very high degree of confidence that the tumor findings in the experimental animals are not relevant…

Life sciences; biologyApplied psychologyMechanism of tumorigenesisGuidelines as TopicCommissionAir Pollutants Occupational010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentGerman03 medical and health sciences0302 clinical medicineGovernment AgenciesSpecies SpecificityTumor Findingsddc:570GermanyNeoplasmsOccupational ExposureAnimalsHumansHuman relevance0105 earth and related environmental sciencesCarcinogenicitySpecies-specific tumorsMaximally tolerated doseInternational AgenciesGeneral Medicinelanguage.human_languageOccupational DiseasesCategorizationlanguageCarcinogensDegree of confidencePsychologyAnimal tumor studiesOrgan-specific tumors
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct